Posted by Michael Wonder on 06 Sep 2020
Venclyxto in combination with obinutuzumab is included in the high-cost protection with limitation
28 August 2020 - Venclyxto (venetoclax) is already included in the high-cost protection with limited subsidy.
Venclyxto is now also subsidised for use in combination with Gazyvaro (obinutuzumab) for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.
The previous subsidy limit for Venclyxto means that it was only subsidised for use in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia who have received at least one previous treatment.
